Online citations, reference lists, and bibliographies.
← Back to Search

Gene Therapy For Psoriasis In The K14‐VEGF Transgenic Mouse Model By Topical Transdermal Delivery Of Interleukin‐4 Using Ultradeformable Cationic Liposome

J. Li, Xia Li, Y. Zhang, X. Zhou, H. Yang, X. C. Chen, Y. Wang, Y. Q. Wei, L. Chen, H. Hu, Chang Y Liu
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Topical transdermal gene delivery to the skin shows great potential for painless, non‐invasive administration of vaccines and therapeutic agents. Interleukin (IL)‐4 strategies have shown a good antipsoriatic effect in clinic trials. To date, no information has been acquired on the effectiveness of gene therapy for psoriasis in the K14‐VEGF transgenic mouse model by topical transdermal penetration of murine IL‐4 (mIL‐4) using ultradeformable cationic liposome (UCL).
This paper references
10.1016/S0190-9622(03)01141-1
Efalizumab: an overview.
C. Leonardi (2003)
10.1016/S0378-5173(00)00336-7
Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome-plasmid DNA complexes.
J. Birchall (2000)
10.1016/S0140-6736(00)04954-0
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
U. Chaudhari (2001)
10.1016/S1359-6446(04)03180-0
The transdermal revolution.
B. J. Thomas (2004)
10.1002/jgm.620
Skin permeation, biodistribution, and expression of topically applied plasmid DNA
Minjeong Kang (2004)
10.1016/S0140-6736(07)61128-3
Pathogenesis and clinical features of psoriasis
C. Griffiths (2007)
10.1172/JCI1476
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
K. Asadullah (1998)
with cytokine - expression plasmids induces strong antigen - specific immune responses
RW Groves (2001)
10.1038/nature05663
Pathogenesis and therapy of psoriasis
M. A. Lowes (2007)
10.1007/s00403-005-0602-8
The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment
Ayca Cordan Yazici (2005)
10.1016/MJD.2003.554
Etanercept: An overview.
B. Goffe (2003)
10.1016/j.biocel.2008.10.022
Interplay between keratinocytes and immune cells--recent insights into psoriasis pathogenesis.
G. Tonel (2009)
10.1111/j.1365-2133.1992.tb07805.x
Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T‐cell derived cytokines?
B. Baker (1992)
10.1038/nm804
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
K. Ghoreschi (2003)
10.1111/j.1365-2133.1991.tb00419.x
Endothelial leucocyte adhesion molecule‐1 (ELAM‐1) expression in cutaneous inflammation
R. Groves (1991)
10.1038/74480
Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex
A. Domashenko (2000)
10.1016/S0264-410X(01)00324-3
Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
L. J. Liu (2001)
10.1111/J.1749-6632.1991.TB27260.X
Overview and Evolution of Therapeutic Systems
A. Zaffaroni (1991)
10.1016/S0190-9622(03)01143-5
Infliximab for psoriasis.
A. Gottlieb (2003)
10.1053/BERH.2001.0187
The balance of Th1/Th2 cytokines in rheumatoid arthritis.
H. Schulze-Koops (2001)
10.1046/J.1523-1747.1999.00513.X
Topical gene delivery to murine skin.
W. Yu (1999)
10.1038/nbt928
Discovery of transdermal penetration enhancers by high-throughput screening
P. Karande (2004)
10.1084/JEM.178.1.87
Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice
M. Rapoport (1993)
10.1056/NEJM200107263450403
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
C. Ellis (2001)
Topical application of HIV DNA
LJ Liu
10.1016/S0190-9622(89)70073-6
Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor.
C. E. Griffiths (1989)
10.1046/J.0022-202X.2001.01317.X
Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.
K. Asadullah (2001)
10.1002/JPS.10061
Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles.
Nalini Raghavachari (2002)
10.1038/NM0597-476
Animal models of psoriasis
M. Schoen (1997)
10.1182/BLOOD-2002-12-3793
Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.
Y. Xia (2003)
10.1136/pgmj.2007.061473
Psoriasis: advances in pathophysiology and management
A. Macdonald (2007)
10.1038/nrd1304
Current status and future potential of transdermal drug delivery
M. Prausnitz (2004)
10.1016/J.JAAD.2005.04.035
Psoriasis--recent advances in understanding its pathogenesis and treatment.
G. Krueger (2005)
10.1016/0190-9622(93)70154-L
Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon gamma.
R. Groves (1993)
10.1111/j.1396-0296.2004.04045.x
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis
T. Patel (2004)
10.1016/MJD.2003.552
Development and use of alefacept to treat psoriasis.
G. Krueger (2003)
10.1016/J.BIOMATERIALS.2004.02.020
Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes.
Eun Hye Lee (2005)
10.1016/S0142-9612(03)00534-9
In vitro and in vivo transfection efficiency of a novel ultradeformable cationic liposome.
A. Kim (2004)
10.1211/002235702289
Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix)
S. Babiuk (2002)



This paper is referenced by
10.2147/CCID.S39559
Utilization of biodegradable polymeric materials as delivery agents in dermatology
F. Rancan (2014)
Psoriasis: Molecular targets of denervation and therapy
E. M. Baerveldt (2013)
10.1142/9789814520652_0024
Nanoparticles for Dermal and Transdermal Delivery: Permeation Pathways and Applications
M. Foldvari (2014)
10.1002/9781118354377.CH23
Dicationic gemini nanoparticle design for gene therapy
Mahmoud Elsabahy (2013)
10.1590/S0325-00752011000300009
[Gene therapy: nucleic acids as drugs. Action mechanisms and delivery into the cell].
B. Cavagnari (2011)
10.1016/B978-0-323-42978-8.00007-3
Peptide and Protein-Based Therapeutic Agents
Mary Joseph (2017)
10.1371/journal.pone.0058196
IL-23 Induces Atopic Dermatitis-Like Inflammation Instead of Psoriasis-Like Inflammation in CCR2-Deficient Mice
S. Bromley (2013)
10.1517/14712598.2011.579096
Hox transcription factor regulation of adult bone-marrow-derived cell behaviour during tissue repair and regeneration
Elahe Mahdipour (2011)
10.1016/j.jdermsci.2014.03.001
Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation.
Jiaolin Wen (2014)
10.1016/j.ejps.2011.04.003
Lipid-mediated gene delivery to the skin.
B. Geusens (2011)
10.1016/j.vascn.2019.106657
Murine models of psoriasis and its applications in drug development.
T. Luo (2019)
10.1007/s40005-015-0219-7
Delivery of biopharmaceuticals using combination of liposome and iontophoresis: a review
Santosh K Bashyal (2015)
10.4049/jimmunol.1401740
IL-4 Downregulates IL-1β and IL-6 and Induces GATA3 in Psoriatic Epidermal Cells: Route of Action of a Th2 Cytokine
A. Onderdijk (2015)
10.1007/s13671-014-0092-z
Perspectives on Using Nanoscale Delivery Systems in Dermatological Treatment
M. Foldvari (2015)
10.1155/2013/149695
Transdermal Delivery of Small Interfering RNA with Elastic Cationic Liposomes in Mice
Y. Hattori (2013)
10.1016/j.jconrel.2015.12.012
Non-viral gene therapy: Gains and challenges of non-invasive administration methods.
M. Foldvari (2016)
10.1517/17425247.2012.735658
Liposomal delivery of proteins and peptides
Janani Swaminathan (2012)
10.1201/9781420002126
FOR GENE THERAPY
Mahmoud Elsabahy (2013)
10.1007/s00109-015-1338-3
Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines
Yangping Wu (2015)
Development of photosensitive liposomes for the controlled release of drugs
Pranav Bhujbal (2016)
10.1016/j.ejpb.2019.02.012
Lipid gene nanocarriers for the treatment of skin diseases: Current state‐of‐the‐art
C. Bellefroid (2019)
10.1016/j.jdermsci.2014.07.012
Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.
T. Hemmerle (2014)
10.1016/j.cis.2020.102121
Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation.
F. Bayat (2020)
10.1158/2326-6066.CIR-13-0182
The Dose-Dependent Tumor Targeting of Antibody–IFNγ Fusion Proteins Reveals an Unexpected Receptor-Trapping Mechanism In Vivo
T. Hemmerle (2014)
10.5897/AJPPX12.001
Novel topical drug carriers as a tool for treatment of psoriasis: Progress and advances
P. Suresh (2013)
10.1016/j.jphs.2015.05.008
Anti-psoriatic effects of Honokiol through the inhibition of NF-κB and VEGFR-2 in animal model of K14-VEGF transgenic mouse.
Jiaolin Wen (2015)
10.2174/1381612821666150416100516
Application of nano- and micro-particles on the topical therapy of skin-related immune disorders.
Lin Sun (2015)
10.1007/978-94-007-6010-3_6
Cationic Liposome-Based Systems for Nucleic Acid Delivery: From the Formulation Development to Therapeutic Applications
H. Faneca (2013)
10.1016/j.jconrel.2015.09.017
Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.
Michael Zakrewsky (2015)
10.1016/j.omtn.2020.04.003
Skin Delivery of siRNA Using Sponge Spicules in Combination with Cationic Flexible Liposomes
Xuejiao Liang (2020)
Advances in Predictive, Preventive and Personalised Medicine
S. Karabulut (2012)
This information is current as Route of Action of a Th 2 Cytokine Cells : Induces GATA 3 in Psoriatic Epidermal and IL-6 and β IL-4 Downregulates IL-1
Armanda J. Onderdijk (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar